|
|
|
| Bioequivalence of oral candesartan cilexetil capsules in healthy volunteers |
| GUO Zhe1, QIANG LieYing1, ZHU Zhe1, WANG Hui1,BI Jingfeng1,and WEI Zhenman2 |
1. Department of Pharmacy, Second Hospital of Beijing Municipal Corps; Chinese People’s Armed Police Force, Beijing 100037, China;
2. The Center of New Drug Clinical Trial, No.302 Hospital of PLA, Beijing 100039, China |
|
|
|
|
Abstract Objective To study the bioequivalence of the tested and reference oral candesartan Cilexetil in healthy male volunteers. Methods According to the crossover design,each volunteer was orally given 8 mg candesartan cilexetil capsules or tablets. Their plasma concentrations were determined by LC/MS/MS. Pharmacokinetic parameters were obtained using DAS program. Results Cmax were(79.62±29.99) ng/ml and (77.74±28.46) ng/ml,AUC0-t were (850.17±249.52) ng/(ml· h)and (837.26±243.26)ng/(ml· h),AUC0-∞ were (908.96±249.64) ng/(ml· h) and(896.94±241.53) ng/(ml· h),respectively. Two-way unilateral t-test results showed that the test preparation did not exceed the prescribed upper limit and lower limit of the reference preparation, rejected null hypothesis (P＜0.05). The 90% confidence intervals of Cmax,AUC0-t and AUC0-∞were between the standard of reference tablets (80%-125%). Conclusions Candesartan cilexetil capsules and candesartan cilexetil tablets are bioequivalent.
|
|
Received: 12 February 2015
|
|
|
|
|
|
| [2] |
俞 佳,马 珂,祁金文,等.坎地沙坦酯片和胶囊在健康人体的药代动力学和生物等效性[J]. 中国临床药理学与治疗学, 2009,14(7):794-798.
|
| [3] |
化学药物制剂人体生物利用度和生物等效性研究技术指导原则课题研究组. 化学药物制剂人体生物利用度和生物等效性研究技术指导原则[EB/OL]. [2012-11-14].
|
| [4] |
刘梅讯,雷枫琴. 坎地沙坦对高血压合并2型糖尿病患者血浆尾加压素Ⅱ和脂联素的影响[J]. 中国循证心血管医学杂志, 2013,5(5):470-472.
|
| [1] |
朱余兵,邹建军,钱 薇,等.健康受试者口服复方坎地沙坦酯片后坎地沙坦的药代动力学研究[J].中国临床药理学与治疗学, 2007, 12(4): 474-477.
|
| [2] |
俞 佳,马 珂,祁金文,等.坎地沙坦酯片和胶囊在健康人体的药代动力学和生物等效性[J]. 中国临床药理学与治疗学, 2009,14(7):794-798.
|
| [5] |
陈 凌,潘静蔽,秦永文,等.坎地沙坦酯治疗轻中度高血压患者的疗效及安全性[J]. 药学服务与研究, 2004, 2(4): 139-141.
|
| [3] |
化学药物制剂人体生物利用度和生物等效性研究技术指导原则课题研究组. 化学药物制剂人体生物利用度和生物等效性研究技术指导原则[EB/OL]. [2012-11-14].
|
| [6] |
李卫华. 坎地沙坦联合其他抗高血压药物治疗原发性高血压的疗效观察[J]. 临床合理用药, 2014,7(5):56-57.
|
| [7] |
段元青.坎地沙坦酯片治疗原发性高血压的成本效果分析[J].泰山医学院学报,2014,35(10):1029-1031.
|
| [4] |
刘梅讯,雷枫琴. 坎地沙坦对高血压合并2型糖尿病患者血浆尾加压素Ⅱ和脂联素的影响[J]. 中国循证心血管医学杂志, 2013,5(5):470-472.
|
| [8] |
邓智建,袁 宇,曹冬梅.坎地沙坦西酯治疗慢性心力衰竭40例[J].中国药师,2008,11(9):1087-1089.
|
| [5] |
陈 凌,潘静蔽,秦永文,等.坎地沙坦酯治疗轻中度高血压患者的疗效及安全性[J]. 药学服务与研究, 2004, 2(4): 139-141.
|
| [9] |
丁玉林,马小虎,冶明星. 美托洛尔联合坎地沙坦酯片治疗老年中重度高血压58例[J].中国药业,2013,22(19):97-98.
|
| [6] |
李卫华. 坎地沙坦联合其他抗高血压药物治疗原发性高血压的疗效观察[J]. 临床合理用药, 2014,7(5):56-57.
|
| [10] |
朱燕妮, 傅潞仙, 徐飞瑶, 等. 高效液相色谱法对坎地沙坦酯固体分散体颗粒溶出度的测定[J].中国医药导报, 2013, 10(3): 127-129.
|
| [7] |
段元青.坎地沙坦酯片治疗原发性高血压的成本效果分析[J].泰山医学院学报,2014,35(10):1029-1031.
|
| [11] |
朱余兵, 于翠霞, 程俊霖, 等. 复方坎地沙坦酯片在健康受试者体内的生物等效性研究[J]. 中国药师,2011,14(6):775-778.
|
| [8] |
邓智建,袁 宇,曹冬梅.坎地沙坦西酯治疗慢性心力衰竭40例[J].中国药师,2008,11(9):1087-1089.
|
| [12] |
徐 戎, 斯陆勤, 顾世芬, 等. 国产和进口坎地沙坦酯片人体生物等效性评价[J]. 中国药学杂志, 2008, 43(6): 455-458.
|
| [9] |
丁玉林,马小虎,冶明星. 美托洛尔联合坎地沙坦酯片治疗老年中重度高血压58例[J].中国药业,2013,22(19):97-98.
|
| [10] |
朱燕妮, 傅潞仙, 徐飞瑶, 等. 高效液相色谱法对坎地沙坦酯固体分散体颗粒溶出度的测定[J].中国医药导报, 2013, 10(3): 127-129.
|
| [11] |
朱余兵, 于翠霞, 程俊霖, 等. 复方坎地沙坦酯片在健康受试者体内的生物等效性研究[J]. 中国药师,2011,14(6):775-778.
|
| [12] |
徐 戎, 斯陆勤, 顾世芬, 等. 国产和进口坎地沙坦酯片人体生物等效性评价[J]. 中国药学杂志, 2008, 43(6): 455-458.
|
|
|
|
2015, Vol. 26 
